Read our latest paper on TumorMapr and see how spatial analytics can reshape understanding cancer, published in Nature Communications : Read here ->
SpIntellx is ushering a new era of unbiased spatial analytics and explainable AI in precision pathology at AACR 2022 SpIntellx announces that it will attend
Thank you to everyone who visited our booth during the 2022 United States & Canadian Academy of Pathology (USCAP) 111th Annual Meeting in Los Angeles.
PRESIDENT, CO-FOUNDER, &
CHIEF TECHNOLOGY OFFICER
Chakra earned his PhD from the Department of Computer Science at the University of Toronto specializing in computer vision, machine learning and AI. Chakra was tenured Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh.
Chakra co-founded SpIntellx to actualize the translational potential of these Pitt IP-fueled platforms. Chakra’s experience encompasses years in both industry and academia. He was the lead PI on several National Institutes of Health and National Science Foundation grants covering broad areas of bioimaging, molecular biophysics, computational and systems biology, and spatial intratumor heterogeneity. He holds several patents and has published extensively, appearing in Science Translational Medicine and Nature Communications, among other prominent journals.
CHIEF EXECUTIVE OFFICER
B. Dusty Majumdar, PhD is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years. Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur. He has authored several peer-reviewed scientific publications and holds multiple patents.
Sr. VP Business Development
Joe Camaratta specializes in medical technology innovation and commercialization, taking products from concept to clinical adoption. He held executive positions for GE Healthcare and Siemens Healthcare and built businesses in medical imaging, cardiology, and oncology. He founded and led two early stage medical technology companies that apply artificial intelligence to improve clinical decision-making.
Joe holds a Master of Science degree in Computer Science from Rutgers University and a Bachelor of Science degree in Computer Science from Drexel University. He currently serves as an advisor to the Entreprenuerial Investing Program of the Crohn’s & Colitis Foundation, and the University Science Center QED Program focused on commercialization of academic innovations
EXECUTIVE CHAIRMAN & CO-FOUNDER
Dr. Taylor is currently the Director of the University of Pittsburgh Drug Discovery Institute managing the collaborative programs involving clinicians, biomedical scientists, chemists, engineers and systems biologists at Pitt, Carnegie Mellon University, the University of Pittsburgh Medical Center, as well as external collaborators from academia, federal agencies and industry.
Lans was Co-Founder and CEO of Cellomics Inc., which developed and commercialized High Content Screening (HCS) that permitted single cell quantitation of multiplexed fluorescence biomarkers in arrays of cells and tissues. In addition to Cellomics, Dr. Taylor co-founded several other biotech companies, such as Biological Detection Systems, Inc. and Cernostics, Inc., and is an expert in multiplexed fluorescence and biomarker imaging.